Heart valve disease presenting in adults: investigation and management
In development [GID-NG10122] Expected publication date: 08 September 2021
Search results
546 results
-
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs only have failed (partial review of TA375) [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Atrial fibrillation: management
In development [GID-NG10100] Expected publication date: 12 March 2021
-
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated non-small-cell lung cancer (CDF Review of TA557) [ID1584]
In development [GID-TA10529] Expected publication date: 10 March 2021
-
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]
In development [GID-TA10595] Expected publication date: TBC
-
Mepolizumab for treating severe eosinophilic asthma [ID3750]
In development [GID-TA10622] Expected publication date: 03 February 2021
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
In development [GID-TA10451] Expected publication date: TBC
-
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID1313]
In development [GID-TA10312] Expected publication date: 24 February 2021
-
Tobacco: preventing uptake, promoting quitting and treating dependence (update)
In development [GID-NG10086] Expected publication date: 01 September 2021
-
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education
In development [GID-NG10113] Expected publication date: 19 January 2022
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management
In development [GID-NG10185] Expected publication date: TBC
-
Chronic kidney disease: assessment and management (update)
In development [GID-NG10118] Expected publication date: 30 June 2021
-
Inducing labour (update)
In development [GID-NG10082] Expected publication date: 14 October 2021
-
Caesarean section (update)
In development [GID-NG10081] Expected publication date: 31 March 2021
-
Relugolix with oestradiol and norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: TBC
-
Subarachnoid haemorrhage due to ruptured aneurysms
In development [GID-NG10097] Expected publication date: 21 July 2021
-
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
In development [GID-TA10474] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: 22 September 2021
-
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]
In development [GID-TA10538] Expected publication date: TBC
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Non-bisphosphonates for treating osteoporosis [ID901]
In development [GID-TA10072] Expected publication date: 19 May 2021
-
Multiple myeloma - lenalidomide (maintenance, post autologous stem cell transplantation) [ID475]
In development [GID-TAG430] Expected publication date: 24 February 2021
-
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]
In development [GID-TA10613] Expected publication date: 13 October 2021
-
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]
In development [GID-TA10456] Expected publication date: 27 January 2021
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor [ID1468]
In development [GID-TA10351] Expected publication date: 27 January 2021
-
Neonatal infection: antibiotics for prevention and treatment
In development [GID-NG10111] Expected publication date: 12 April 2021
-
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593) [ID3755]
In development [GID-TA10675] Expected publication date: 17 June 2021
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]
In development [GID-TA10644] Expected publication date: 17 March 2021
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: 17 March 2021
-
Anakinra for treating active Stills disease [ID1463]
In development [GID-TA10392] Expected publication date: TBC
-
Weight Management
In development [GID-NG10182] Expected publication date: 22 June 2022
-
Babies, children and young people's experience of healthcare
In development [GID-NG10119] Expected publication date: 25 August 2021
-
Thyroid cancer: assessment and management
In development [GID-NG10150] Expected publication date: 22 June 2022
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Barrett's oesophagus: ablative therapy
In development [GID-NG10165] Expected publication date: 23 January 2023
-
Depression in adults: treatment and management (update)
In development [GID-CGWAVE0725] Expected publication date: 12 May 2022
-
Ponesimod for treating relapsing multiple sclerosis [ID1393]
In development [GID-TA10556] Expected publication date: 17 November 2021
-
Self harm: assessment, management and preventing recurrence
In development [GID-NG10148] Expected publication date: 18 May 2022
-
Gout: diagnosis and management
In development [GID-NG10151] Expected publication date: 13 June 2022
-
Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]
In development [GID-TA10520] Expected publication date: 15 September 2021
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Rehabilitation after traumatic injury
In development [GID-NG10105] Expected publication date: 23 November 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Chronic pain: assessment and management
In development [GID-NG10069] Expected publication date: TBC
-
Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC